Today announced it will be presenting at the Digestive Disease Week (DDW 2022) Conference taking place May 21-24, 2022, in San Diego, California.
The research will be focused on developing new treatments for Inflammatory Bowel Disease (IBD)
Clearance for Proof-of-Concept Phase I human trial in oncology received from Israeli Ministry of Health
The results demonstrate the efficacy of Biomica’s live bacterial consortia, BMC333, for the treatment of IBD
Biomica expects to initiate first-in-human, proof-of-concept study later this year
Today announced that Dr. Elran Haber, Chief Executive Officer of Biomica, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday, April 22, 2021.
Biomica’s live biotherapeutic drug candidate, BMC128, significantly increased anti-tumor activity in combination with Immune Checkpoint Inhibitors in Melanoma. First-in-human, proof of concept study expected later this year
Today announced it will be featured as a presenting company at the Microbiome Movement Drug Development Europe Conference.
The company is advancing to scale-up and GMP batch production, to support anticipated first-in-man proof-of-concept clinical trials next year
